Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry



      Although secondary cardiovascular prevention is a focus among patients with type 2 diabetes (T2D) and coronary artery disease (CAD) or peripheral artery disease (PAD), the application of guideline-recommended therapy in T2D patients and isolated cerebrovascular disease (CeVD) remains unknown.


      In a US outpatient registry, T2D patients with established cardiovascular disease from 2014-2018 were categorized as: isolated CeVD, CeVD plus CAD or PAD, or isolated CAD/PAD. In each group, we determined the proportion with optimal secondary prevention (hemoglobin [Hb]A1C <8%, blood pressure <130/80 mm Hg, use of antithrombotics, use of statins, non-smoking/cessation counseling, and use of glucose-lowering medications with cardioprotective effects (sodium-glucose cotransporter [SGLT]-2 inhibitors, glucagon-like peptide [GLP]-1 receptor agonists, thiazolidinediones [TZDs]). Hierarchical Poisson regression was used to estimate relative rate of achieving each target across groups, adjusted for age and chronic kidney disease (where relevant).


      Our study included 727,467 T2D outpatients with cardiovascular disease (isolated CeVD [n = 99,777], CeVD plus CAD/PAD [n = 158,361], isolated CAD/PAD [n = 469,329]). Compared with isolated CAD/PAD patients, isolated CeVD patients more often had an HbA1c <8% (adjusted relative risk [aRR] 1.10; 95% confidence interval [CI], 1.08-1.11) but less often had a blood pressure of ≤130/80 mm Hg (aRR 0.93; 95% CI, 0.92-0.94) or were prescribed antithrombotics (0.84; 95% CI, 0.83-0.85), statins (0.86; 95% CI, 0.85-0.87), GLP-1 agonists (0.75; 95% CI, 0.73-0.78), SGLT2 inhibitors (0.73; 95% CI, 0.71-0.76), and TZDs (aRR 0.76; 95% CI, 0.73-0.78).


      Among T2D patients, those with isolated CeVD had the lowest rates of secondary cardiovascular prevention goals attainment. More focus is needed on secondary prevention in patients with CeVD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Luitse MJA
        • Biessels GJ
        • Rutten GEHM
        • Kappelle LJ
        Diabetes, hyperglycaemia, and acute ischaemic stroke.
        Lancet Neurol. 2012; 11: 261-271
        • Arnold SV
        • de Lemos JA
        • Rosenson RS
        • et al.
        Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease.
        Circulation. 2019; 140: 618-620
        • McGuire DK
        • Shih WJ
        • Cosentino F
        • et al.
        Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.
        JAMA Cardiol. 2020; 6: 148-158
        • Honigberg MC
        • Chang LS
        • McGuire DK
        • Plutzky J
        • Aroda VR
        • Vaduganathan M
        Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review.
        JAMA Cardiol. 2020; 5: 1182-1190
        • Kernan WN
        • Viscoli CM
        • Furie KL
        • et al.
        Pioglitazone after ischemic stroke or transient ischemic attack.
        N Engl J Med. 2016; 374: 1321-1331
        • Jauch EC
        • Saver JL
        • Adams HP
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947
        • Kernan WN
        • Ovbiagele B
        • Black HR
        • et al.
        Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2014; 45: 2160-2236
        • Arnold SV
        • Inzucchi SE
        • McGuire DK
        • et al.
        Evaluating the quality of comprehensive cardiometabolic care for patients with type 2 diabetes in the U.S.: the Diabetes Collaborative Registry.
        Diabetes Care. 2016; 39: e99-e101
        • de Boer IH
        • Bangalore S
        • Benetos A
        • et al.
        Diabetes and hypertension: a position statement by the American Diabetes Association.
        Diabetes Care. 2017; 40: 1273-1284
        • Qaseem A
        • Wilt TJ
        • Kansagara D
        • et al.
        Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians.
        Ann Intern Med. 2018; 168: 569-576
        • Bushnell CD
        • Olson DM
        • Zhao X
        • et al.
        Secondary preventive medication persistence and adherence 1 year after stroke.
        Neurology. 2011; 77: 1182-1190
        • Glader EL
        • Sjölander M
        • Eriksson M
        • Lundberg M
        Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.
        Stroke. 2010; 41: 397-401
        • Bushnell CD
        • Zimmer LO
        • Pan W
        • et al.
        Persistence with stroke prevention medications 3 months after hospitalization.
        Arch Neurol. 2010; 67: 1456-1463
        • American Diabetes Association
        10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes–2021.
        Diabetes Care. 2021; 44: S125-S150
        • Al Hamed FA
        • Elewa H
        Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke.
        Clin Ther. 2020; 42: e242-e249
        • Tsapas A
        • Avgerinos I
        • Karagiannis T
        • et al.
        Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis.
        Ann Intern Med. 2020; 173: 278-286
        • Zinman B
        • Inzucchi SE
        • Lachin JM
        • et al.
        Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk.
        Stroke. 2017; 48: 1218-1225
        • Reeves MJ
        • Vaidya RS
        • Fonarow GC
        • et al.
        Quality of care and outcomes in patients with diabetes hospitalized with ischemic stroke: Findings from get with the guidelines-stroke.
        Stroke. 2010; 41: e409-e417
        • Echouffo-Tcheugui JB
        • Xu H
        • Matsouaka RA
        • et al.
        Diabetes and long-term outcomes of ischaemic stroke: findings from get with the guidelines-stroke.
        Eur Heart J. 2018; 39: 2376-2386
        • Zinman B
        • Wanner C
        • Lachin JM
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Neal B
        • Perkovic V
        • Mahaffey KW
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Wiviott SD
        • Raz I
        • Bonaca MP
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • McMurray JJ V
        • Solomon SD
        • Inzucchi SE
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008